| Literature DB >> 33545036 |
Alberto Sada Japp1, Wenzhao Meng2, Aaron M Rosenfeld2, Daniel J Perry3, Puchong Thirawatananond3, Rhonda L Bacher4, Chengyang Liu5, Jay S Gardner1, Mark A Atkinson3, Klaus H Kaestner6, Todd M Brusko3, Ali Naji5, Eline T Luning Prak7, Michael R Betts8.
Abstract
Ahmed and colleagues recently described a novel hybrid lymphocyte expressing both a B and T cell receptor, termed double expresser (DE) cells. DE cells in blood of type 1 diabetes (T1D) subjects were present at increased numbers and enriched for a public B cell clonotype. Here, we attempted to reproduce these findings. While we could identify DE cells by flow cytometry, we found no association between DE cell frequency and T1D status. We were unable to identify the reported public B cell clone, or any similar clone, in bulk B cells or sorted DE cells from T1D subjects or controls. We also did not observe increased usage of the public clone VH or DH genes in B cells or in sorted DE cells. Taken together, our findings suggest that DE cells and their alleged public clonotype are not enriched in T1D. This Matters Arising paper is in response to Ahmed et al. (2019), published in Cell. See also the response by Ahmed et al. (2021), published in this issue.Entities:
Keywords: HIRN; HPAP; Human Islet Research Network; Human Pancreas Analysis Program; T1D; immune repertoire; immunoglobulin; immunophenotyping; public clone; rare-event detection; type 1 diabetes
Mesh：
Substances：
Year: 2021 PMID： 33545036 PMCID： PMC8016147 DOI： 10.1016/j.cell.2020.11.035
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582